Literature DB >> 19208887

Comparative evaluation of three commercial Toxoplasma-specific IgG antibody avidity tests and significance in different clinical settings.

Branko Bobić1, Ivana Klun1, Marija Vujanić1, Aleksandra Nikolić1, Vladimir Ivović1, Tijana Živković1, Olgica Djurković-Djaković1.   

Abstract

Determination of the avidity of specific IgG antibodies has become a generally accepted diagnostic aid for dating Toxoplasma infection. In this study, the Labsystems, VIDAS and EUROIMMUN Toxoplasma IgG avidity assays were compared on a series of 133 Toxoplasma IgG- and IgM-positive sera from symptomatic patients (n=28), from pregnant (n=43) and non-pregnant (n=26) women, and on 18 IgG-positive and IgM-negative sera from chronically infected patients. The results showed excellent concordance between the Labsystems and VIDAS tests in both the IgM-positive (r=0.82, kappa=0.771) and IgM-negative (kappa=0.609) sera, whilst the agreement of the EUROIMMUN assay with both the Labsystems and VIDAS tests in the IgM-positive sera was moderate (kappa=0.575 and kappa=0.525, respectively) and in the IgM-negative sera was poor (kappa=0.000). Analysis of the kinetics of the maturation of avidity in 13 patients in whom follow-up sera were available showed that, despite a general trend of maturation, in two patients the avidity did not become high during 6 and 11 months of follow-up. In view of the clinical setting, in the symptomatic patients, despite one case of complete discrepancy and five cases of partial discrepancy, the Labsystems and VIDAS tests were in almost perfect agreement (kappa=0.812), whilst the agreement in pregnant and non-pregnant women was substantial (kappa=0.754 and kappa=0.708, respectively). In conclusion, the Labsystems and VIDAS tests are equally reliable for the measurement of Toxoplasma IgG avidity; the choice of test should depend on the laboratory set-up. The EUROIMMUN test may be an acceptable alternative in resource-limited settings, but should be used prudently.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208887     DOI: 10.1099/jmm.0.006668-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  14 in total

1.  Adverse fetal outcome in the absence of timely prenatal diagnosis of congenital toxoplasmosis.

Authors:  Tijana Zivković; Vladimir Ivović; Marija Vujanić; Ivana Klun; Branko Bobić; Aleksandra Nikolić; Olgica Djurković-Djaković
Journal:  Wien Klin Wochenschr       Date:  2011-10-20       Impact factor: 1.704

2.  Interpretation of the Elecsys Toxo IgG avidity results for very low and very high index: study on 741 sera with a determined date of toxoplasmosis.

Authors:  H Fricker-Hidalgo; C L'Ollivier; C Bosson; S Imbert; S Bailly; C Dard; R Piarroux; L Paris; H Pelloux
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-19       Impact factor: 3.267

3.  Evaluation of the new Elecsys Toxo IgG avidity assay for toxoplasmosis and new insights into the interpretation of avidity results.

Authors:  Jean-Benjamin Murat; Coralie L'Ollivier; Hélène Fricker Hidalgo; Jacqueline Franck; Hervé Pelloux; Renaud Piarroux
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

4.  Comparison of four commercially available avidity tests for Toxoplasma gondii-specific IgG antibodies.

Authors:  O Villard; L Breit; B Cimon; J Franck; H Fricker-Hidalgo; N Godineau; S Houze; L Paris; H Pelloux; I Villena; E Candolfi
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

5.  Identification, production and assessment of two Toxoplasma gondii recombinant proteins for use in a Toxoplasma IgG avidity assay.

Authors:  Ai Ying Teh; Atefeh Amerizadeh; Sabariah Osman; Muhammad Hafiznur Yunus; Rahmah Noordin
Journal:  Pathog Glob Health       Date:  2016-10-04       Impact factor: 2.894

6.  Toxoplasma seroconversion with negative or transient immunoglobulin M in pregnant women: myth or reality? A French multicenter retrospective study.

Authors:  H Fricker-Hidalgo; B Cimon; C Chemla; M L Darde; L Delhaes; C L'ollivier; N Godineau; S Houze; L Paris; D Quinio; F Robert-Gangneux; O Villard; I Villena; E Candolfi; H Pelloux
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

Review 7.  Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.

Authors:  Bettie Voordouw; Barry Rockx; Thomas Jaenisch; Pieter Fraaij; Philippe Mayaud; Ann Vossen; Marion Koopmans
Journal:  Clin Microbiol Rev       Date:  2019-12-11       Impact factor: 26.132

8.  The necessity of confirmatory testing in serodiagnosis of toxoplasmosis in iran.

Authors:  Mehrzad Saraei; Seyedeh Zeinab Fattahi; Mojtaba Shahnazi; Afshin Afshari; Safar Ali Alizadeh; Hassan Jahanihashemi
Journal:  Iran J Parasitol       Date:  2013-10       Impact factor: 1.012

9.  Comparison of Toxoplasma gondii IgG avidity Architect and Vidas assays with the estimated date of infection in pregnant women.

Authors:  Aurélie Smets; Thomas Fauchier; Grégory Michel; Pierre Marty; Christelle Pomares
Journal:  Parasite       Date:  2016-10-20       Impact factor: 3.000

10.  Prenatal and Early Postnatal Diagnosis of Congenital Toxoplasmosis in a Setting With No Systematic Screening in Pregnancy.

Authors:  Tijana Stajner; Branko Bobic; Ivana Klun; Aleksandra Nikolic; Jelena Srbljanovic; Aleksandra Uzelac; Irena Rajnpreht; Olgica Djurkovic-Djakovic
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.